Tan R A
Antelope Valley Allergy Medical Group, Palmdale, CA 93551, USA.
Curr Opin Pulm Med. 1998 Jan;4(1):25-30. doi: 10.1097/00063198-199801000-00005.
The antileukotriene agents are the first new category of asthma medications introduced in the past two decades. Leukotriene synthesis inhibitors block the production of leukotrienes whereas leukotriene receptor antagonists block the effects of leukotrienes at the receptor level. Leukotriene synthesis inhibitors are further classified as either 5-lipoxygenase inhibitors or 5-lipoxygenase-activating protein inhibitors. Zafirlukast, montelukast, and pranlukast are leukotriene receptor antagonists whereas zileuton is a 5-lipoxygenase inhibitor. Antileukotrienes have been shown to be relatively safe and effective in chronic mild to moderate asthma. Studies are ongoing to determine how they compare with inhaled steroids, which remain the drug of choice for anti-inflammatory therapy.
抗白三烯药物是过去二十年来推出的首个新型哮喘药物类别。白三烯合成抑制剂可阻断白三烯的生成，而白三烯受体拮抗剂则在受体水平阻断白三烯的作用。白三烯合成抑制剂进一步分为5-脂氧合酶抑制剂或5-脂氧合酶激活蛋白抑制剂。扎鲁司特、孟鲁司特和普仑司特是白三烯受体拮抗剂，而齐留通是一种5-脂氧合酶抑制剂。抗白三烯药物已被证明在慢性轻至中度哮喘中相对安全有效。目前正在进行研究以确定它们与吸入性类固醇相比如何，吸入性类固醇仍是抗炎治疗的首选药物。
